Relmada Therapeutics Reports CMO–Urology Departure Sept 3, 2026

What Happened
Relmada Therapeutics, Inc. (RLMD) filed an 8-K on September 8, 2026, announcing that Dr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology ended effective September 3, 2026. The company reported this as an "Other Event" (Item 8.01) in the filing and provided no additional substantive details about the departure.

Key Details

• Dr. Raj S. Pruthi’s title: Chief Medical Officer – Urology.
• Employment end date: September 3, 2026.
• Form filed: 8-K, reported under Item 8.01 (Other Events) on September 8, 2026.
• The filing did not disclose reasons for the departure, a successor, or terms of any separation.

Why It Matters
A C-suite clinical executive change can affect oversight of clinical programs and regulatory communications. For investors, the immediate facts are limited to the departure itself; shareholders should watch for follow-up disclosures (e.g., an 8-K under Item 5.02 or press release) about a replacement, interim leadership, or any impact on Relmada’s clinical development plans.